肝肾综合征——缩血管还是扩血管?  

Hepatorenal syndrome-vasoconstrictor or vasodilator?

作　　者：徐小元[1] 郑颖颖[1] 

机构地区：[1]北京大学第一医院感染疾病科,北京100034

出　　处：《临床肝胆病杂志》2011年第8期801-803,817,共4页Journal of Clinical Hepatology

摘　　要：肝肾综合征(HRS)是发生在严重肝脏疾病中的并发症,病死率很高。其主要特征为无其他病因的肾功能受损,肾小球滤过和肾血浆流量显著降低。在HRS的研究中,具有重大意义的发现是,内脏和周围血管循环复杂的改变、全身循环系统和肾脏局部缩管物质和舒血管物质失调,进而导致的肾脏血管的强烈收缩。近年多个临床实验结果显示缩血管物质联合白蛋白静脉输注可以改善短期治疗结果,成为临床内科治疗的热点。Hepatorenal syndrome （HRS） is a common complication of serious liver disease with a very high mortality, and is characterized by marked reduction in glomerular filtration rate （GFR） and renal plasma flow（RPF） in the absence of other cause of renal failure. The researches of great significance showed that HRS related to renal vasoconstriction with predominant peripheral arterial vasodilation, resulting from complex changes in splanehnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators. Recently, some clinical trials have indicated that vasoconstrictor combined with albumin infusion have emerged as the preferred pharmacologic therapies for management of HRS and could improve short -- term outcome.

关 键 词：肝肾综合征 

分 类 号：R575[医药卫生—消化系统]